UCB SA

ROYALTY MONETIZATION

August 2020

MarketerUCB SA

VIMPAT® (lacosamide) is one of the leading established brands for the treatment of epilepsy.  The product, which first received FDA approval in October 2008 and is marketed by UCB SA, is one of the highest grossing anti-epileptic products in the last decade.

Background

HCR purchased the remaining royalty interest in worldwide sales from one of the inventors of VIMPAT® (lacosamide). The counterparty had a desire to monetize the remaining royalty interest as a means of risk mitigation, diversification of assets and a desire to pursue charitable endeavors.